| 2024/05/03 08:16:07 | |
|---|---|
| Price | |
| 39.685 EUR | |
| Difference | 1.67% (0.65) |
General attributes
| ISIN | NL0015001WM6 |
| Symbol | QGEN |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 8,805 EUR |
| Benchmark | AMSTERDAM EXCHANGES INDEX |
Market data
| Bid (Bid size) | 39.745 EUR (101) |
| Ask (Ask size) | 39.765 EUR (252) |
| Open | 39.685 EUR |
| High | 39.685 EUR |
| Low | 39.685 EUR |
| Close (prev. day) | 39.035 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Futures and Options
| Related Futures | 38 |
| Related Options | - |
PDF Downloads
| Company report: QIAGEN NV |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/03/13 |
|
Global Equity Ratings |
|
| 2024/02/22 |
|
Global Equity Ratings |
|
| 2024/02/14 |
|
Global Equity Ratings |
|
| 2024/05/03 08:16:07 | |
|---|---|
| Price | |
| 39.685 EUR | |
| Difference | 1.67% (0.65) |
General attributes
| ISIN | NL0015001WM6 |
| Symbol | QGEN |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 8,805 EUR |
| Benchmark | AMSTERDAM EXCHANGES INDEX |
Market data
| Bid (Bid size) | 39.745 EUR (101) |
| Ask (Ask size) | 39.765 EUR (252) |
| Open | 39.685 EUR |
| High | 39.685 EUR |
| Low | 39.685 EUR |
| Close (prev. day) | 39.035 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | +5.65% | -5.81% | -5.48% |
| Perf (abs.) | +2.09 | -2.41 | -2.26 |
| Beta | 0.28 | 0.53 | 0.47 |
| Volatility | 18.26 | 18.92 | 23.53 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 38.576 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 38.594 EUR (10) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 39.980 EUR (8) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 40.407 EUR (3) |
| YTD High | date | 42.660 EUR (2024/01/09) |
| YTD Low | date | 36.500 EUR (2024/04/19) |
| 52 Weeks High | date | 44.361 EUR (2023/06/05) |
| 52 Weeks Low | date | 35.237 EUR (2023/10/31) |
All listings for QIAGEN NV
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2024/05/03 | 09:30 | 39.74 EUR | 0.47 | 149 |
| Vienna Stock Exchange | 2024/05/03 | 09:12 | 39.61 EUR | 0.02 | 4 |
| Tradegate | 2024/05/03 | 08:45 | 39.75 EUR | 0.00 | 1 |
| Stuttgart | 2024/05/03 | 09:30 | 39.73 EUR | 0.03 | 20 |
| SIX Swiss Exchange | 2019/06/28 | 17:35 | 39.45 CHF | 0.00 | 1 |
| NYSE | 2024/05/02 | 22:00 | 42.68 USD | 51.18 | 14,741 |
| Munich | 2024/05/03 | 08:02 | 39.89 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2024/05/02 | 17:30 | 43.54 EUR | 0.00 | 2 |
| Hanover | 2024/05/03 | 08:16 | 39.685 EUR | 0.00 | 1 |
| Hamburg | 2024/05/03 | 08:16 | 39.685 EUR | 0.00 | 1 |
| Frankfurt | 2024/05/03 | 09:15 | 39.705 EUR | 0.00 | 2 |
| Euronext Milan MTF Trading After Hours | 2024/04/08 | 18:55 | 39.18 EUR | 0.00 | 1 |
| Euronext Milan MTF Global Equity Market | 2024/05/02 | 17:44 | 39.545 EUR | 0.00 | 3 |
| Duesseldorf | 2024/05/03 | 08:12 | 39.685 EUR | 0.00 | 1 |
| Berlin | 2024/05/03 | 08:02 | 39.69 EUR | 0.00 | 1 |
Company Logo
Contact Details
| QIAGEN NV |
| - - |
| Hulsterweg 82 - 5912 PL Venlo |
| Telefon: +31-77-355-66-00 |
| Fax: + |
| E-mail: qiagen@qiagen.com |
PDF Downloads
| Company report: QIAGEN NV | |
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. |
Members of Management Board
| Thierry Bernard | Chairman of Managing Board |
| Jonathan Sheldon | Member of Executive Committee |
| Philipp von Hugo | Member of Executive Committee |
| Thomas Schweins | Member of Executive Committee |
| Ulrich Schriek | Member of Executive Committee |
| Antonio Santos | Member of Executive Committee |
| Jean-Pascal Viola | Member of Executive Committee |
| John Gilardi | Member of Executive Committee |
| Lezette Young | Member of Executive Committee |
| Nedal Safwat | Member of Executive Committee |
| Roland Sackers | Member of Executive Committee |
| Stephany Foster | Member of Executive Committee |
Board of directors
| Lawrence Rosen | Chairman of Supervisory Board |
| Elaine Mardis | Member of Supervisory Board |
| Eva Pisa | Member of Supervisory Board |
| Metin Colpan | Member of Supervisory Board |
| Ross Levine | Member of Supervisory Board |
| Toralf Haag | Member of Supervisory Board |
| Bert van Meurs | Member of Supervisory Board |
| Elizabeth Tallett | Member of Supervisory Board |
| Eva van Pelt | Member of Supervisory Board |
| Stephen Rusckowski | Member of Supervisory Board |